VenaCure 1470-nm Laser


COMPANY AngioDynamics
PHONE (800) 772-6446
WEB www.angiodynamics.com
KEY FEATURES

  • Uses lower power output compared with other lasers to achieve effective vein closure
  • System includes a choice of procedure kits, procedure accessories, and a tumescent delivery system
  • Uses NeverTouch gold-tip fiber technology

AngioDynamics (Queensbury, NY) has expanded its VenaCure EVLT system product offering with the global launch of the new VenaCure 1470-nm laser to treat varicose veins with greater energy efficiency.

The VenaCure 1470-nm laser's light energy is precisely delivered through the NeverTouch gold-tip fiber and is more readily absorbed by the water in the blood and endothelial lining than is the case with other wavelengths, the company stated. The NeverTouch fiber's jacketed tip has been engineered to maximize clinical efficacy and minimize postoperative pain and bruising. It has a lower power density and is designed to virtually eliminate the risk of direct contact between the laser fiber and vein wall.

“We found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period,” Jose I. Almeida, MD, FACS, Managing Partner of Vascular Device Partners, LLC, said. “By allowing for the more efficient transfer of energy to the vein, this new long-wavelength laser translated into improved clinical outcomes as compared to short-wavelength lasers we have studied.”

The VenaCure 1470-nm laser has received the CE Mark and a 510(k) clearance.



Exoseal Vascular Closure Device


COMPANY Cordis Corporation
PHONE (908) 541-4100
WEB www.cordis.com
KEY FEATURES

  • Made entirely of a synthetic, absorbable PGA
  • PGA plug material is constructed to stop bleeding from the puncture site
  • Uses a standard introducer sheath
  • Incorporates two markers that provide visual targets to determine the location of the plug relative to the outside of the vascular wall
  • Comes fully assembled

The Exoseal vascular closure device (Cordis Corporation, Bridgewater, NJ) is FDA cleared for use in diagnostic and interventional procedures, making use of key technological developments to support the clinical safety of the closure procedure. In the ECLIPSE trial, Exoseal use was associated with no embolization, infection, or other major adverse events, comparable to manual compression (despite the significantly shorter time to ambulation for Exoseal). The bioabsorbable polyglycolic acid (PGA) plug, which is designed to close the femoral artery puncture site with minimal or no inflammation, is fully reabsorbed in 60 to 90 days. PGA is a noncollagen plug material that is metabolized to carbon dioxide and water. A system of deployment through the existing procedural sheath helps make Exoseal quick, easy to use, and convenient because there is no need for sheath exchange during the procedure, the company stated. The device uses visual indicators to help the physician deploy the device correctly. This visual feedback also promotes patient comfort during deployment by minimizing tugging and pulling, and the Exoseal lockout system helps clinicians to achieve proper extravascular plug placement.



AFX Endovascular AAA System


COMPANY Endologix
PHONE (800) 983-2284 or (949) 595-7200
WEB www.endologix.com
KEY FEATURES

  • Low-profile introducer sheath for smooth tracking and delivery
  • Highly predictable and accurate deployment
  • Uses a standard introducer sheath
  • Strata multilayer ePTFE graft material for strength and conformability

The AFX endovascular abdominal aortic aneurysm (AAA) system (Endologix, Irvine, CA) is a newly US Food and Drug Administration–approved low-profile stent graft system for the treatment of AAAs. The system lowers the profile of delivery with a single 17-F hydrophilic-coated introducer sheath through which all devices are deployed. It provides a precise deployment dial for accurate placement. The new AFX stent graft incorporates Endologix's latest innovation in graft material, Strata multilayered ePTFE, for both strength and conformability.



DuraMax Chronic Dialysis Catheter


COMPANY AngioDynamics
PHONE (800) 772-6446
WEB www.angiodynamics.com
KEY FEATURES

  • Luer fittings constructed of thermoplastic polyurethane combine chemical resistance and superior dimensional stability
  • Polyester cuff material allows optimal tissue in growth and catheter securement
  • Available in a full range of catheter lengths, including a 48-cm length, in both basic kit and catheter-only configurations

AngioDynamics (Queensbury, NY) has announced the launch of the next-generation DuraMax stepped-tip chronic dialysis catheter. This 15.5-F, high-flow/highperformance design features proprietary curved-tip catheter technology. The catheter tip is designed to reduce arterial insufficiency, provide superior over-the-wire performance, and improve ease of use during catheter insertion. A dedicated guidewire lumen securely centers the guidewireat the leading edge of the venous tip. The curved-tip profile helps prevent arterial insufficiency and maintains flows in the event of vessel wall apposition. Clinical blood flow rates of 400 mL/min at modest arterial pressures have been reported by initial users at 30 days. The innovative lumen profile provides a large inner diameter to support high flow rates and improved kink resistance to ensure optimal clinical outcomes in tortuous vessels, the company stated. The new ergonomically designed packaging is compact includes the SafeSheath D-Pro, a hemostaticvalved insertion sheath for dialysis catheter placement.



Aptus EndoStapling System


COMPANY Aptus Endosystems, Inc.
PHONE (408) 530-9050
WEB www.aptusendosystems.com
KEY FEATURES

  • Helical staples designed to reproduce the integrity of a hand-sutured anastomosis
  • Simplifies revision surgery for migration and type I endoleak
  • Augments the inherent sealing and fixation mechanisms of an endograft during de novo implantationh
  • Allows physician control over the degree and specific locations of each point of fixation, tailored to the individual patient's anatomy

The Aptus EndoStapling system (Aptus Endosystems, Inc., Sunnyvale, CA) is an innovative helical staple technology for use in endovascular aneurysm repair (EVAR). The system enables independent endograft fixation and is designed to reproduce the physical integrity and durability of the hand suturing performed during open surgical repair of abdominal aortic aneurysms. The EndoStapling system provides physicians with a novel technology to repair endovascular grafts that have exhibited migration or endoleaks (or are at risk of these complications) where augmented radial fixation and/or sealing is required to regain or maintain effective aortic aneurysm exclusion. The system can also be used during de novo EVAR procedures to enhance an endograft's inherent fixation and sealing mechanisms. The EndoStaple and EndoStapling system have been evaluated and determined to be compatible with the Zenith (Cook Medical); Excluder (Gore & Associates); and AneuRx, Endurant, and Talent (Medtronic, Inc.) endografts. Use with other endografts has not been evaluated.

The Aptus EndoStapling system bears the CE Mark for distribution in the European Union; the system is an investigational device in the United States.